Friday, 16 October 2026European Markets

ROCHE BOBOIS And BURELLE Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - roche bobois (rbo.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
roche bobois (rbo.pa) €40.60 4.98% 35.83%
burelle (bur.pa) €487.00 2.96% 4.63%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. roche bobois (rbo.pa)

4.98% forward dividend yield and 35.83% return on equity

roche bobois s.a. engages in the furniture design and distribution business worldwide. it provides living room products, such as sofas and sofa beds, coffee tables, armchairs, wall compositions, cocktail tables, tv units, bookcases, cabinets, side tables, consoles, and occasional furniture; dining room products, including chairs, stools, benches, sideboards, dining tables, columns, dressers, and dining room storage products; desks; bedroom products comprising beds, wardrobes, bedside tables, screens, complements, and other bedroom furniture products; outdoor furniture products; and lights, cushions, rugs, mirrors, decorative objects, and home furnishings, as well as other furniture products. the company offers its products under the roche bobois and cuir center brands. as of march 31, 2022, it operated 128 owned and 210 franchised stores in 56 countries worldwide, as well as an online store. the company was formerly known as furn-invest s.a.s. roche bobois s.a. was founded in 1960 and is headquartered in paris, france.

earnings per share

as for profitability, roche bobois has a trailing twelve months eps of €1.98.

pe ratio

roche bobois has a trailing twelve months price to earnings ratio of 20.51. meaning, the purchaser of the share is investing €20.51 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 35.83%.

revenue growth

year-on-year quarterly revenue growth grew by 27.2%, now sitting on 377.35m for the twelve trailing months.

volatility

roche bobois's last week, last month's, and last quarter's current intraday variation average was a negative 0.13%, a negative 0.05%, and a positive 1.43%.

roche bobois's highest amplitude of average volatility was 0.88% (last week), 1.45% (last month), and 1.43% (last quarter).

more news about roche bobois.

2. burelle (bur.pa)

2.96% forward dividend yield and 4.63% return on equity

burelle sa, through its subsidiaries, offers automotive equipment, intelligent body systems, and clean energy systems and modules in france and internationally. the company offers plastic and composite body parts and systems, and fuel and pollution control systems; researches and develops lightweight vehicles, pollution control systems, and support for new engines; and develops, assembles, and provides logistics for automotive front-end modules. it also operates a venture capital company that invests in various companies through a network of family offices, investment funds, and financial institutions; and owns an office building in levallois, as well as various real estate assets in the lyon region. burelle sa was founded in 1957 and is headquartered in lyon, france.

earnings per share

as for profitability, burelle has a trailing twelve months eps of €-66.1.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.63%.

moving average

burelle's worth is under its 50-day moving average of €510.26 and higher than its 200-day moving average of €480.85.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, burelle's stock is considered to be overbought (>=80).

more news about burelle.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com